AstraZeneca entered into a definitive agreement Monday to acquire CinCor Pharma Inc. for up to $1.8 billion.
CinCor (NASDAQ: CINC), based in Waltham, Massachusetts, is developing new treatments for hypertension and chronic kidney disease. The company’s stock was up 137% at $27.91 per share in early morning trading.
The deal, which still requires shareholder and regulatory approval, is expected to be completed during the first quarter of this year.
Mene Pangalos, executive vice president for…
